Format

Send to

Choose Destination
See comment in PubMed Commons below
Med Hypotheses. 2010 Dec;75(6):572-5. doi: 10.1016/j.mehy.2010.07.034. Epub 2010 Aug 12.

Is it time to reassess alpha lipoic acid and niacinamide therapy in schizophrenia?

Author information

1
Department of Kinesiology and Human Nutrition, University of Illinois at Chicago, 1919 Taylor, Chicago, IL 60612, USA. sejs@att.net

Abstract

As sulfur containing thiols, alpha lipoic acid (ALA) and its reduced form dihydrolipoic acid (DHLA) are powerful antioxidants and free radical scavengers capable of performing many of the same functions as glutathione (GSH). ALA supplementation may help protect mitochondria from oxidative stress, a possible mechanism contributing to certain forms of brain diseases called schizophrenia. Shortly before the advent of antipsychotic medications, two small studies found ALA relieved psychiatric symptoms in schizophrenia. More recently, animal studies have shown ALA augmentation improves mitochondrial function. At pharmaceutical levels, niacinamide helps preserve mitochondrial membrane integrity and acts as an antioxidant. ALA is a precursor for lipoamide, an essential mitochondrial coenzyme and niacinamide is a component of niacinamide adenine dinucleotide (NAD). NADH, the reduced form of NAD, is involved in the reduction of ALA to DHLA within the mitochondria. This is relevant to contemporary research because DHLA increases GSH and low GSH levels contribute to mitochondrial dysfunction and oxidative stress which have been implicated in the pathophysiology of schizophrenia.

PMID:
20708342
DOI:
10.1016/j.mehy.2010.07.034
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center